Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Science Sweden´s Editor-in-Chief, in an editorial.

New diagnostic test soon ready for the market

"Imponerande kraftsamling gav vaccin"

Det rekordsnabba framtagandet av nya vaccin under pandemin visar vad läkemedelsindustrin – och mänskligheten – kan åstadkomma när pressen är tillräckligt stor.

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct site in the gastrontestinal tract are two of them.

Giulia Gaudenzi: ”Key lessons from global health research”

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Swedish and Danish Life Science – are there still untapped synergies?

With the increasing developments in life sciences over the past decade and strong support for the sector’s strategic importance from both the Sweden and Danish governments, the timing of The Future of Swedish & Danish Life Science conference could not be better. A one-day conference on ongoing collaborations, new directions and required future investment will held on April 2nd at Medicon Village in Lund.

Upcoming event: New updates on drugs

At Medicon Valley Alliance venues in Copenhagen/Örestad April 1 2020 the meeting New updates in Drug Formulation & Bioavailability takes place for the for the eighth time.

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of Development at Spago Nanomedical says.

Meet the governmental life science office

More clinical trials, promotion for digitisation and interoperability together with increased use of data generated by both healthcare and individuals. The duties of the Life Sciences office are plentiful.

The best wealth is Health

We are living in a world where wealth more and more is measured in being able to do the things you like and enjoy in life. As the wealth increases in terms of economic strength, the expectation of a long and healthy life increases and with that a demand of enjoy life.

Swedish life science in political focus

It feels like 2017 will be a good year for Swedish life science, says Anders Blanck, CEO at LIF.

Hon är årets innovationsängel

Jennie Ekbeck från Umeå Biotech Incubator tilldelas innovationspris.

Karin Meyer lämnar PCG

Karin Meyer går till nytt jobb.

Hon tar över EU-support

Tuulikki Lindmark är ny på posten.

Konkurs för Creative

Creative Antibiotics avbryter rekonstruktion och ansöker om konkurs.

Creative Antibiotics undgår likvidation

Blir rekonstruktion i stället. Umeåbolaget kommer att vara kvar på Aktietorget och ansöka om företagsrekonstruktion.

Creative Antibiotics varslar personalen

Vid en årsstämma i slutet av maj väntas bolaget träda i likvidation. Personalen har varslats om uppsägning.

Creative Antibiotics likvideras

Styrelse och ledning hittar inga sätt att finansiera bolagets fortsatta verksamhet.

Creative Antibiotics likvideras

Efter en turbulent vår slås nu sista spiken i kistan för Creative Antibiotics. Vid en extra bolagsstämma i slutet av maj väntas styrelsen föreslå att företaget likvideras.

Handeln med Creatives aktie återupptas

Aktien stannar dock kvar på Aktietorgets observationslista.

Instabilt för Creative Antibiotics

Creative Antibiotics lyckas inte återskapa de positiva resultaten från tidigare djurstudier och hotas nu av rekonstruktion eller avveckling.